Cognition Therapeutics, Inc.

NasdaqGM:CGTX Voorraadrapport

Marktkapitalisatie: US$18.9m

Cognition Therapeutics Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Cognition Therapeutics's earnings have been declining at an average annual rate of -27.3%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually.

Belangrijke informatie

-27.3%

Groei van de winst

81.7%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie6.0%
Inkomstengroein/a
Rendement op eigen vermogen-135.1%
Nettomargen/a
Laatste winstupdate30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Can Cognition Therapeutics (NASDAQ:CGTX) Afford To Invest In Growth?

Sep 06
Can Cognition Therapeutics (NASDAQ:CGTX) Afford To Invest In Growth?

Cognition Therapeutics: Shines Less Bright After Phase 2 Results In Alzheimer's Disease

Jul 31

Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?

May 22
Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?

Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer's

Apr 18

Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation

Nov 30
Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation

Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?

Aug 15
Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?

Cognition Therapeutics (NASDAQ:CGTX) Is In A Good Position To Deliver On Growth Plans

Mar 17
Cognition Therapeutics (NASDAQ:CGTX) Is In A Good Position To Deliver On Growth Plans

Cognition stock rises 12% on $2.14M grant from NIH for Alzheimer's study

Sep 27

We Think Cognition Therapeutics (NASDAQ:CGTX) Can Afford To Drive Business Growth

Aug 12
We Think Cognition Therapeutics (NASDAQ:CGTX) Can Afford To Drive Business Growth

Cognition's Alzheimer's candidate demonstrates mechanism of action; shares soar

Aug 05

We're Not Very Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate

Mar 19
We're Not Very Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate

Opbrengsten en kosten

Hoe Cognition Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

NasdaqGM:CGTX Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 240-311345
31 Mar 240-291442
31 Dec 230-261437
30 Sep 230-231332
30 Jun 230-231429
31 Mar 230-241429
31 Dec 220-211330
30 Sep 220-241729
30 Jun 220-221425
31 Mar 220-191221
31 Dec 210-161019
30 Sep 210-12516
30 Jun 210-10416
31 Mar 210-9414
31 Dec 200-12513

Kwaliteitswinsten: CGTX is currently unprofitable.

Groeiende winstmarge: CGTX is currently unprofitable.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: CGTX is unprofitable, and losses have increased over the past 5 years at a rate of 27.3% per year.

Versnelling van de groei: Unable to compare CGTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: CGTX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).


Rendement op eigen vermogen

Hoge ROE: CGTX has a negative Return on Equity (-135.09%), as it is currently unprofitable.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden